8:30 : WELCOME COFFEE (KURSAAL)
9:15-12:00 : SESSION #3 : Early-Stage Clinical Trials
Chairpersons : Dr Sylvain Perruche, Med’Inn’Pharma and xx, FR
09:15 : CAR-T cell in autoimmune diseases: from the laboratory to clinical applications
Pr Dominique Farge-Bancel, CRMR MATHEC, Hôpital St-Louis, AP-HP, Université Paris Cité, Paris, FR
09:45 : Translating MSC Exosome Science into Therapy: Preclinical Evidence and First-in-Human Trial for Psoriasis
Pr Sai Kiang Lim, Paracrine Therapeutics, Singapour
10:15 : BREAK- EXHIBITION HALL
11:00 : The challenges of translating Pluripotent Stem Cell-derived therapies compared to somatic cell therapies: from starting material to product purity
Dr Jo Mountford, Scottish National Blood Transfusion Service, Edinburgh, UK
11:30 : ATMP regulation in the USA: how does it differ from the EU?
Pr Erika Lietzan, University of Missouri-Columbia, Columbia, USA
12:00-14:00 : LUNCH & Exhibition Hall
12:40-14:00 : B2B MEETINGS
14:00-16:30 : SESSION #4 : SCALE-UP AND GO TO MARKET
Chairpersons : Dr Christophe Ferrand and Dr Marina Deschamps, Right Institute, Besançon, FR
14:00 : Journey of India’s First Indigenous CAR-T Therapy
Dr Rahul Purwar, ImmunoACT, Bombay, India
14:30 : Upcoming title (Innovation for scalable CAR-T production)
Guillaume Wallart, Cellquest, Besançon, FRA
15:00 : BREAK- EXHIBITION HALL
15:30 : ATMP release : from phase I to commercial stage
Dr Hélène Nègre, Cell For Cure by Seqens, Les Ulis, FRA
16:00 : CAR-T therapy for adult ALL: opportunities and challenges
Dr Claire Roddie, Autolus, London, UK
16:45-16:50 : CONCLUSION & END OF CONGRESS
Dr Marina Deschamps, RIGHT Institute, Besançon, FR
Renaud Gaudillière, PMT director